Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):August 30, 2004
MYLAN LABORATORIES INC.
| Pennsylvania | 1-9114 | 25-1211621 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
1500 Corporate Drive
Canonsburg, PA 15317
(Address of principal executive offices)
(724) 514-1800
(Registrant’s telephone number, including area code)
Table of Contents
Item 8.01 Other Events.
On August 30, 2004, Mylan Laboratories Inc., a Pennsylvania corporation, issued a press release announcing that Mylan Pharmaceuticals Inc. has filed a notice of voluntary dismissal without prejudice in the U.S. District Court for the Northern District of West Virginia in its lawsuit against the Food and Drug Administration on the issue of authorized generics. A copy of the press release is attached hereto as Exhibit 99.1, and the August 30, 2004 letter to the court, as referred to in the release, is attached as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits.
| (c) | Exhibits. |
| Exhibit No. | Description | |
| 99.1 | Press release of the registrant, dated August 30, 2004. | |
| 99.2 | Letter dated August 30, 2004, from counsel to Mylan Pharmaceuticals Inc. to the U.S. District Court for the Northern District of West Virginia. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MYLAN LABORATORIES INC. | ||||
| Date: August 30, 2004 | By: | /s/ Edward J. Borkowski | ||
| Edward J. Borkowski | ||||
| Chief Financial Officer | ||||